Status: Recruiting
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.
Participants needed: 180
Trial details
Phase: Phase 2Age: 18-99Biological sex: AllType: InterventionalSponsor: AmgenUpdated: Jun 18, 2026Locations: 23
Eligibility criteria
Age ≥ 18 years. [+7]
Recent or planned surgical/device-based obesity treatment (<1 year). [+12]